226 related articles for article (PubMed ID: 17221253)
1. [Revision of the recommendations of the Commission on Pharmacotherapy of the German society for Rheumatology. Therapy with tumour necrosis factor blockers for inflammatory rheumatic illnesses].
Manger B; Michels H; Nüsslein HG; Schneider M; Sieper J;
Z Rheumatol; 2007 Feb; 66(1):72-5. PubMed ID: 17221253
[TBL] [Abstract][Full Text] [Related]
2. Tumour necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (REMICADE).
Bondeson J; Maini RN
Int J Clin Pract; 2001 Apr; 55(3):211-6. PubMed ID: 11351775
[TBL] [Abstract][Full Text] [Related]
3. [Revised recommendations of the Deutsche Gesellschaft für Rheumatologie on therapy with tumor necrosis factor-inhibiting active substances on inflammatory diseases].
Manger B;
Z Rheumatol; 2002 Dec; 61(6):694-7. PubMed ID: 12491133
[No Abstract] [Full Text] [Related]
4. Clinical inquiries. Are DMARDs effective for rheumatologic diseases besides rheumatoid arthritis?
Goodemote P; Jamieson B; Hoffman R
J Fam Pract; 2007 Nov; 56(11):933-4, 937. PubMed ID: 17976342
[No Abstract] [Full Text] [Related]
5. MonitorNet: the Italian multi-centre observational study aimed at estimating the risk/benefit profile of biologic agents in real-world rheumatology practice.
Sfriso P; Salaffi F; Montecucco CM; Bombardieri S; Todesco S
Reumatismo; 2009; 61(2):132-9. PubMed ID: 19633800
[TBL] [Abstract][Full Text] [Related]
6. The 2005 International Symposium on Advances in Targeted Therapies: what have we learned in the 2000s and where are we going?
Maini RN
Ann Rheum Dis; 2005 Nov; 64 Suppl 4():iv106-8. PubMed ID: 16239377
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
[TBL] [Abstract][Full Text] [Related]
8. Drug insight: Anti-tumor necrosis factor therapy for inflammatory arthropathies during reproduction, pregnancy and lactation.
Skomsvoll JF; Wallenius M; Koksvik HS; Rødevand E; Salvesen KA; Spigset O; Kvien TK
Nat Clin Pract Rheumatol; 2007 Mar; 3(3):156-64. PubMed ID: 17334338
[TBL] [Abstract][Full Text] [Related]
9. [Recommendations of the German Society of Rheumatology for therapy with tumor necrosis factor inhibitors. Pharmacotherapy Committee of the German Society of Rheumatology].
Z Rheumatol; 2000 Aug; 59(4):291-2. PubMed ID: 11013988
[No Abstract] [Full Text] [Related]
10. Tumour necrosis factor inhibitors in ankylosing spondylitis.
Reed MR; Taylor AL
Intern Med J; 2008 Oct; 38(10):781-9. PubMed ID: 18422565
[TBL] [Abstract][Full Text] [Related]
11. Do TNF-blockers reduce or induce uveitis?
Cobo-Ibáñez T; del Carmen Ordóñez M; Muñoz-Fernández S; Madero-Prado R; Martín-Mola E
Rheumatology (Oxford); 2008 May; 47(5):731-2. PubMed ID: 18346974
[No Abstract] [Full Text] [Related]
12. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register.
Kristensen LE; Gülfe A; Saxne T; Geborek P
Ann Rheum Dis; 2008 Mar; 67(3):364-9. PubMed ID: 17644547
[TBL] [Abstract][Full Text] [Related]
13. [Current status of basic antirheumatic therapy].
Keitel W
Fortschr Med; 1994 Oct; 112(30):419-22. PubMed ID: 7806117
[TBL] [Abstract][Full Text] [Related]
14. Immunological therapies for rheumatoid arthritis.
Edwards CJ
Br Med Bull; 2005; 73-74():71-82. PubMed ID: 16174791
[TBL] [Abstract][Full Text] [Related]
15. Methotrexate and anti-tumor necrosis factor treatment improves endothelial function in patients with inflammatory arthritis.
Deyab G; Hokstad I; Whist JE; Smastuen MC; Agewall S; Lyberg T; Ronda N; Mikkelsen K; Hjeltnes G; Hollan I
Arthritis Res Ther; 2017 Oct; 19(1):232. PubMed ID: 29041979
[TBL] [Abstract][Full Text] [Related]
16. [Inflammatory rheumatic diseases].
Kellner H
MMW Fortschr Med; 2009 Apr; 151(14):67-70; quiz 71. PubMed ID: 19504844
[No Abstract] [Full Text] [Related]
17. Clinical trial outcome of anti-tumour necrosis factor alpha therapy in rheumatic arthritis.
Choy E
Cytokine; 2004 Nov 21-Dec 7; 28(4-5):158-61. PubMed ID: 15588689
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of ankylosing spondylitis and undifferentiated spondyloarthritis with TNF alpha-antagonists].
Brandt J; Sieper J; Braun J
Z Rheumatol; 2003 Jun; 62(3):218-27. PubMed ID: 12827397
[TBL] [Abstract][Full Text] [Related]
19. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.
Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Bijlsma JW; Dougados M; Emery P; Keystone EC; Klareskog L; Mease PJ
Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv2-14. PubMed ID: 16239380
[No Abstract] [Full Text] [Related]
20. Multidisciplinary focus on methotrexate in psoriatic disesase.
Marchesoni A; Ricci M; Moggio E; Brazzelli V; Borroni G
J Rheumatol Suppl; 2009 Aug; 83():56-8. PubMed ID: 19661543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
